EUVIMEDEUVIMED entdecken
Crossref

Safeguarding Patients in the AI Era: Ethics at the Forefront of Pharmacovigilance

Ashish Jain iD, Maribel Salas iD, Omar Aimer iD, Zahabia Adenwala iD

Drug Safety · 2025

DOI: 10.1007/s40264-024-01483-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Safety, 2025. Verfasst von Ashish Jain und 3 weiteren Autor:innen. Beteiligte Einrichtung: Curis Inc., 128 Spring Street, Suite 500, Lexington, MA, 02421, USA. JainashishL89@gmail.com. Hauptthemen laut MEDLINE: Artificial Intelligence, Pharmacovigilance. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Artificial intelligence is increasingly being used in pharmacovigilance. However, the use of artificial intelligence in pharmacovigilance raises ethical concerns related to fairness, non-discrimination, compliance, and responsibility as the central ethical principles in risk assessment and regulatory requirements. This paper explores these concerns and provides a roadmap to how to address these challenges by considering data collection, privacy protection, transparency and accountability, model training, and explainability in artificial intelligence decision making for drug safety surveillance. A number of responsible approaches have been identified including an ethics framework and best practices to enhance artificial intelligence use in healthcare. The document also recognizes some initiatives that have demonstrated the importance of ethics in artificial intelligence pharmacovigilance. Nevertheless, the major needs mentioned in this paper are transparency, accountability, data protection, and fairness, which stress the necessity of collaboration to construct a cognitive framework aimed at integrating ethical artificial intelligence into pharmacovigilance. In conclusion, innovation should be balanced with ethical responsibility to enhance public health outcomes as well as patient safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Artificial IntelligencePharmacovigilanceHumansAdverse Drug Reaction Reporting SystemsDrug-Related Side Effects and Adverse ReactionsPatient SafetyRisk Assessment

Autor:innen und Institutionen

  • Curis Inc., 128 Spring Street, Suite 500, Lexington, MA, 02421, USA. JainashishL89@gmail.com.
  • Bayer Pharmaceuticals, Whippany, NJ, USA.
  • Innovigilance, Montreal, QC, Canada.
  • Seres Therapeutics, Cambridge, MA, USA.

ORCID-Profile: Ashish Jain, Maribel Salas, Omar Aimer, Zahabia Adenwala

Zitieren

APA

Jain, A., Salas, M., Aimer, O., & Adenwala, Z. (2025). Safeguarding Patients in the AI Era: Ethics at the Forefront of Pharmacovigilance. Drug Safety. https://doi.org/10.1007/s40264-024-01483-9

Vancouver

Jain A, Salas M, Aimer O, Adenwala Z. Safeguarding Patients in the AI Era: Ethics at the Forefront of Pharmacovigilance. Drug Safety. 2025. doi:10.1007/s40264-024-01483-9

BibTeX
@article{Jain2025,
  author = {Jain, Ashish and Salas, Maribel and Aimer, Omar and Adenwala, Zahabia},
  title = {Safeguarding Patients in the AI Era: Ethics at the Forefront of Pharmacovigilance},
  journal = {Drug Safety},
  year = {2025},
  doi = {10.1007/s40264-024-01483-9}
}
Kostenlos starten →